Form 4: Pulmonx Director Daniel P. Florin Receives Significant Equity Grant

Pulmonx Corp. Director Daniel P. Florin was granted 37,153 Restricted Stock Units (RSUs) as part of his compensation, aligning his interests with shareholders.

Summary

• Daniel P. Florin, a Director of Pulmonx Corp. (LUNG), was granted 37,153 shares of common stock in the form of Restricted Stock Units (RSUs) on June 2, 2025.
• The RSU grant was made at a price of $0, indicating it is a compensation award rather than a purchase.
• Following this transaction, Mr. Florin beneficially owns a total of 93,910 shares of common stock.
• The total beneficial ownership includes 15,789 shares previously reported as indirectly owned through the Kelly A Florin Trust.
• The RSUs are set to vest on the earlier of (i) the one-year anniversary of the grant date (June 2, 2025, or the next business day) or (ii) the date of the Annual Meeting of Stockholders for the year subsequent to the grant date.

Sentiment

Score: 7

Explanation: The sentiment is positive as the RSU grant aligns the director's interests with shareholders and is a standard form of compensation, indicating continued commitment from the board member. It is not a direct indicator of financial performance but rather a governance and compensation event.

Positives

• The grant of Restricted Stock Units to a director aligns management's and the board's interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• This type of equity compensation is a common practice for retaining and incentivizing key personnel and board members.

Future Outlook

The granted Restricted Stock Units are subject to a vesting schedule, which will occur on the earlier of the one-year anniversary of the grant date (June 2, 2025, or the next business day) or the date of the Annual Meeting of Stockholders for the year subsequent to the grant date.

Industry Context

This Form 4 filing details a routine equity compensation event for a director, common across publicly traded companies to align executive and board interests with shareholder value. It does not provide broader industry trends or competitive insights.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to directors is a standard practice in corporate governance and executive compensation across various industries, including the medical technology sector where Pulmonx operates.
• The vesting schedule, typically over one year or tied to the next annual meeting, is also a common structure designed to retain directors and incentivize long-term performance.

Corporate Governance

Related Party Transactions

• The total beneficial ownership includes 15,789 shares previously reported as indirectly owned through the Kelly A Florin Trust, indicating a related party holding.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with the company's stock performance, potentially leading to decisions that enhance shareholder value.
• Employees: While not directly impacting employees, such compensation practices for directors can reflect a broader company philosophy on incentivizing key personnel.

Next Steps

• Vesting of the 37,153 Restricted Stock Units on the earlier of June 2, 2026, or the date of the Annual Meeting of Stockholders for the year subsequent to the grant date.

Key Dates

Keywords

Pulmonx Corp, LUNG, SEC Form 4, Restricted Stock Units, RSU Grant, Director Compensation, Equity Grant, Insider Transaction, Daniel P. Florin